Brk is for long term, so if they sell might be due to?..

1) free up cash for other growth stock

2) outlook for these companies doesn't look good

3) intending to buy into a competitor? But not likely

4) the segment for these companies don't look good? But pharma is hard to go wrong even for rare diseases...